Title : Metformin dose increase versus added linagliptin in non-alcoholic fatty liver disease and type 2 diabetes: An analysis of the J-LINK study.

Pub. Date : 2021 Mar

PMID : 33236464






1 Functional Relationships(s)
Download
Sentence
Compound Name
Protein Name
Organism
1 We validated effect of linagliptin, an oral dipeptidyl peptidase-4 inhibitor, on nonalcoholic fatty liver disease (NAFLD) in patients with type 2 diabetes mellitus (T2DM). Linagliptin dipeptidyl peptidase 4 Homo sapiens